Guardant Health

We’re looking forward to attending the Oncology Nursing Society’s 50th Annual #ONSCongress this week, where we’ll highlight the vital role oncology nurses play in advancing patient care through molecular testing. Visit us at Booth #4065 to learn how Guardant precision oncology testing contributes to improved patient outcomes. Congress details: https://lnkd.in/eefhxMMv

As March comes to a close, we reflect on the inspiring ways we've united to raise awareness for colorectal cancer. From local events to meaningful conversations, this #ColorectalCancerAwarenessMonth truly showcased a collective dedication to improving cancer outcomes through early detection.   At Guardant Health, we’re proud to be at the forefront of innovation with our Shield™ blood test. By making colorectal cancer screening easier and more accessible, Shield has the potential to reduce preventable deaths and transform the future of cancer detection.   A huge thank you to our employees, partners, and communities who joined us in this important effort this month. Together, we can save more lives.

We’re proud to have teamed up with the Dolphins Cancer Challenge, the largest fundraising event in the National Football League (NFL), to raise awareness for colorectal cancer screening with our Shield™ blood test. This year's event brought together thousands of participants to support innovative cancer research, and we’re grateful to have been part of such a meaningful effort in the fight against cancer.

Today we announced that our Shield™ blood test for colorectal cancer screening is now covered by the U.S. Department of Veterans Affairs Community Care Network. With this coverage, veterans age 45 or older at average risk can access Shield with no copay when receiving community care authorized by the VA. “We are proud of the lifesaving value that the Shield blood test can bring to U.S. veterans and their families,” added our co-CEO AmirAli Talasaz. “This coverage decision by the VA is the first for younger and non-Medicare beneficiaries, and we are excited to broaden the impact of our screening test to help detect more colorectal cancer early, when it is most treatable.”

Our Shield™ blood test has received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services, showing the unique value of the Shield test for CRC screening. This is another step forward in improving colorectal cancer screening rates and expanding patient access. “We’ve already seen strong adoption by providers with Medicare-covered patient populations. This designation from CMS and a more favorable Medicare rate will help us bring the innovation of Shield to more patients coast-to-coast by accelerating our investments in building our commercial infrastructure," added our co-CEO AmirAli Talasaz.

We’re proud to announce a new collaboration with Dak Prescott’s Faith Fight Finish Foundation and the Partners in Wellness program—an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center—to help increase colorectal cancer screening rates in northern and central Louisiana. As part of this effort, the Partners in Wellness mobile screening program will offer our Shield™ blood test at events throughout the region during #ColorectalCancerAwarenessMonth, making colorectal cancer screening more accessible and convenient for underserved communities. Together, we’re bringing critical screening options directly to the communities that need them most—because early detection can save lives. More details: https://lnkd.in/e5ucrjmB

We’re proud to collaborate with the European Coalition for Comprehensive Genomic Profiling (ECGP) initiative to improve patient access and help make comprehensive genomic profiling (CGP) a routine part of cancer care across Europe!

In honor of #ColorectalCancerAwarenessMonth, join us for a special webinar series diving into the latest data from the groundbreaking GOZILA study conducted in Japan. Together, we’ll explore key insights from the 2024 Nature Medicine publication, “Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors” by Nakamura et al., and discuss how this evolving data is shaping the future of precision oncology for colorectal and other gastrointestinal (GI) cancers. 📅 Webinar Dates & Times: March 11: 12:30pm - 1:00pm ET | https://bit.ly/41JuxbG March 12: 1:00pm - 1:30pm ET | https://bit.ly/4ioZ0kM March 12: 7:30pm - 8:00pm ET | https://bit.ly/4boZGUU March 13: 6:00pm - 6:30pm ET | https://bit.ly/4irOlpr

Today marks the start of Colorectal Cancer Awareness Month! A time to come together with partners and communities to support those affected and emphasize the critical role of early detection and screening in the fight against #ColorectalCancer. #ColorectalCancerAwarenessMonth #EarlyDetectionMatters #GetScreened

Over the past few weeks, our Oncology and Screening teams came together for their annual National Sales Meetings — an incredible opportunity to align on strategy, sharpen skills, and celebrate 2024 achievements. With great energy and a shared focus, our teams are ready to embrace the new year and the opportunities ahead, driven by our mission to conquer cancer with data and a relentless commitment to patients. We’re proud to have such a dedicated team representing Guardant in the field. #ChallengeAccepted #OneGuardant